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Abstract
Background: When patients die in a hospital their quality of life is lower than when they die at home or in a
hospice. Despite efforts to improve palliative care supply structures, still about 60% of lung cancer patients die in a
hospital. Studies have examined factors related to inhospital death in lung cancer patients, yet none used data of a
representative German population, additionally including economic aspects. This study aimed to identify factors
related to inhospital death in German lung cancer patients and analysed resulting costs.
Methods: We analysed a dataset of health insurance claims of 17,478 lung cancer patients (incident 2009) with 3
year individual follow-up. We grouped patients into inhospital death and death elsewhere. Studied factors were
indicators of healthcare utilization, palliative care, comorbidities and disease spread. We used logistic regression
models with LASSO selection method to identify relevant factors. We compared all-cause healthcare expenditures
for the last 30 days of life between both groups using generalized linear models with gamma distribution.
Results: Twelve thousand four hundred fifty-seven patients died in the observation period, thereof 6965 (55.9%) in
a hospital. The key factors for increased likelihood of inhospital death were receipt of inpatient palliative care (OR =
1.85), chemotherapeutic treatments in the last 30 days of life (OR = 1.61) and comorbid Congestive Heart Failure
(OR = 1.21), and Renal Disease (OR = 1.19). In contrast, higher care level (OR = 0.16), nursing home residency (OR = 0.
25) and receipt of outpatient palliative care (OR = 0.25) were associated with a reduced likelihood. All OR were
significant (p-values< 0.05). Expenditures in the last 30 days of life were significantly higher for patients with
inhospital death (€ 6852 vs. € 33,254, p-value< 0.0001).
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Conclusion: Findings suggest that factors associated with inhospital death often relate to previous contact with
hospitals like prior hospitalizations, and treatment of the tumour or comorbidities. Additionally, factors associated
with dying elsewhere relate to access to care settings which are more focused on palliation than hospitals. From
these results, we can derive that implementing tools like palliative care into tumour-directed therapy might help
patients make self-determined decisions about their place of death. This can possibly be achieved at reduced
economic burden for SHIs.
Keywords: Lung carcinoma, Place of death, End of life care, Terminal care, Routine data, Palliative care, Health care
supply structures,
Background
In Germany, around 51% of all-cause and tumour-re-
lated deaths occur in a hospital setting, whereupon
males (♂ 57% vs. ♀ 45%) and patients with tumours in
respiratory organs (60% vs. 50%) are affected above aver-
age [1]. Previous research has found that irrespective of
a cancer diagnosis, there is a preference for dying at
home or in a hospice; dying in a hospital setting is
favoured only by few (Gomes 2012, Gomes 2013, Pinzon
2011 and Higginson 2013) [2–5]. A palliative care setting
may help patients express preferences about their place
of death and their preferred treatment based on exten-
sive information. Thus, patients in palliative care settings
may more likely achieve their preferred end of life
choices which supposed to improve their Quality of life
(QoL) at the end of life. Although the number of inhos-
pital deaths has declined in recent years, there is still an
obvious discrepancy between the preferred and the ac-
tual place of death, especially in patients with respiratory
tumours. Furthermore, this patient group is of high
public health relevance, as respiratory tumours were the
fourth leading cause of death in Germany in 2015 [6].
Two studies from the US and the UK found that,
patients’ QoL at the end of life tends to be worse when
they die in a hospital compared to when they die
elsewhere, because they are more likely to experience
physical and emotional distress and feel less at peace [7,
8]. Owing to different framework conditions, generaliz-
ing findings from one health care system to another is a
sensitive issue. Of course, the results of the US-based
study might not be fully replicable in the German
setting, but since both systems are strongly “curatively”
oriented and pay subordinate attention to palliative care,
similar results can be expected for German populations.
Additionally, inpatient care at the end of life generates
higher expenditures than outpatient care as shown by
Gaertner et al. (2013) [9] and Schwarzkopf et al. (2015)
[10]. Thus, reducing the share of inhospital death in lung
cancer patients is in the interest of both the patients
concerned and health care service payers.
Costa (2014) published a systematic review on deter-
minants influencing the place of death of terminally ill
patients [11]. Interprofessional home palliative care and
early referral to palliative services, inter alia, increased
the number of home deaths. Based on these results, the
German palliative care system has been improved, as
Cremer-Schaeffer and Radbruch (2012) reported [12].
Since 2007, every German citizen has a legal claim to
palliative home care. Furthermore, palliative care was
implemented in educational programs for health pro-
fessionals and the number of hospices increased overall.
Consequently, Dasch et al. (2016) showed that the
number of inhospital deaths in German lung cancer
patients decreased between 2001 and 2011 (from 68,1%
to 60,3% in men and from 70,7% to 49,6% in women)
[1]. While trying to determine further factors influen-
cing the place of death, Escobar Pinzón et al. (2011)
found that nonworking relatives and a high care level
are associated with home deaths in the German general
population [4]. A study by Leak et al. (2013) describes
characteristics of 104 lung cancer patients dying in
emergency departments in North Carolina (USA) [13].
71% of those patients died on their first visit and 65%
of them were male. The most common chief complaint
was respiratory distress. Considerably more patients
(n = 143.627) were included in a UK nationwide study
of O’Dowd et al. (2016) [14]. They identified sex, in-
creasing age and social deprivation as factors associated
with inpatient death.
To our knowledge, there is no representative na-
tionwide study for a German population investigating
multiple factors related to inhospital death as well as
related to healthcare expenditures in German lung
cancer patients as of yet.
Therefore, our study aimed to improve the evidence
available by:
a) Defining factors related to inhospital death based
on statutory health insurance (SHI) claims data,
b) using logistic regression models to identify factors
associated with inpatient deaths, and
c) comparing healthcare expenditures in the terminal
phase between patients dying in a hospital and
patients dying elsewhere.
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Methods
Structure of the dataset
For our retrospective claims data analysis, we used
nationwide insurance claims data by the AOK Research
Institute (WIdO) [15] covering about 30% of the
German population. According to the German Guide-
lines for Secondary Data Analysis [16] ethical approval is
generally not required for this type of study. The
German Reporting Standards for Secondary Data
Analyses (STROSA) were considered in the preparation
and implementation of this study [17].
The basic dataset contained anonymized data of
17,478 patients diagnosed with lung cancer in 2009, with
patient-individual three-year follow-up (2009–2012). De-
tails about the sample collection are described elsewhere
[10]. Data included year and month of birth, sex, federal
state of residence, care level (reflecting impairment in
activities of daily living) and nursing home status over
the course of the disease. Additionally, we had informa-
tion on health care service utilization in the in- and out-
patient setting, as well as on corresponding diagnosis
codes (German International Classification of Diseases/
ICD-10-GM) and medical procedures undertaken (OPS/
German Version of the International Classification of
Procedures in Medicine respectively GONR/outpatient
billing codes).
Owing to data protection laws, date of death was only
provided per month. For the purposes of this analyses
we set date of death to the 15th of each month for any
individual observed. Thus, there is an admitted impreci-
sion of up to 2 weeks. To increase precision of date of
death we subsequently checked the discharge status of
hospital stays. Whenever death was documented here,
we replaced the fictive data of death (15th of x) by the
real date of death, which is date of discharge. Regarding
the remainders, we searched for service provision after
the 15th in the month of death. In case of service
provision in the second half of the month, this date was
assumed to be the date of death.
Sample selection
As we compared place of death (inhospital or elsewhere)
in our analysis, we excluded all patients who did not die
within the individual three year follow-up period (n =
3247). One individual was excluded due to implausible
data. To avoid a bias from patients with fulminant pre-
sentations and to focus on patients likely medically
stable enough to have a choice regarding their place of
death, we excluded patients who lived for less than
30 days after diagnosis (n = 1511). We further excluded
any patients who died during the hospital stay of diagno-
sis (n = 115) and those with an implausible date of death,
as they had claims for ambulant palliative treatments
after date of death (n = 23). There are two possible
reasons for claims of treatments after death. Firstly, out-
patient palliative care also includes grief counselling for
the relatives of the deceased. Secondly, as mentioned
above date of death in our study can differ from actual
date of death by a maximum of 2 weeks. Lastly, we ex-
cluded patients with unknown district type of residence
at the time of diagnosis (n = 124). Our final study sample
contained 12,457 patients (Fig. 1).
We assigned patients to the group inhospital death if
the discharge status was ‘death’ in the last hospital visit.
All other patients were assigned to the group of dying
elsewhere.
Factors related to inhospital death
We conducted a literature search in Pubmed in order to
identify factors possibly associated with inhospital death.
Search terms used included “place of death”, “end of life
care”, “quality at the end of life”, and “factors influencing
place of death” preferred for German lung cancer popu-
lations. We considered a potential association between
inhospital death and following factors: age at time of
death, gender, length of survival after diagnosis, nursing
home residency, need for care, residence in Eastern vs.
Western Germany, residence in rural vs. urban area,
palliative care, previous healthcare utilization and treat-
ment pattern, comorbidity burden and disease stage at
diagnosis [4, 11, 13, 14].
Survival was measured as months survived after diag-
nosis. Nursing home residency (yes / no) and need for
care defined as the patient’s care level refer to the last
quarter before death. At the time of data collection, the
German SHI system accounted for three care levels
reflecting the patient’s capabilities to independently
perform activities of daily living. The three levels of
dependency were distinguished by how often assistance
is needed and how long it takes a non-professional
caregiver to help the dependent person. Higher care
levels indicate increased need for assistance (i.e. greater
physical or psychological impairment1) [18]. Living in
Eastern or Western Germany as well as living in an
urban or rural district was defined based on the ZIP
code of the last documented residential address. We
used the district types defined by the Federal Institute
for Research on Building, Urban Affairs and Spatial De-
velopment for 2014, to classify the patients’ residential
area as urban (district type 1 and 2) or rural (district
type 3 and 4) [19].
Palliative care was included as a binary variable
indicating whether palliative care measurements were
administered at least once in an inpatient or outpatients
setting. Information for this came from claims relating
to palliative care codes (OPS for inpatient, GONR for
outpatient palliative care).
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We assessed previous healthcare utilization by calcu-
lating the number of days patients spent in a hospital,
the number of outpatient hospital visits and of out-
patient doctor visits (based on the number of days with
a claim for a GONR) between diagnosis and death. To
factor in collinearity with survival time we divided all
those aspects by survival in months, resulting in
utilization of healthcare by month survived.
To best possibly account for tumour stage at diagnosis
–which is not documented within claims data– we used
the type of tumour-directed therapy patients received
and the location of metastases at baseline. We grouped
patients using inpatient and outpatient ICD-10, OPS,
billing and ATC codes into ‘no tumour-directed therapy’,
‘surgical resection’, ‘radiotherapy’, ‘chemotherapy’ and
combinations of chemotherapy, radiotherapy and surgi-
cal resection. We identified patients with metastases at
baseline using inpatient and verified outpatient ICD 10
codes in the quarters before and after the diagnosis of
lung cancer and grouped them according to location;
into thoracic, cerebral and bone metastases.
To reflect treatment intensity at the end of life, we re-
ported chemotherapy given in the last 30 days before death
as binary variable. This indicator of aggressive treatment
has been used previously in end-of-life research [20].
To assess the patients’ comorbidity burden, we calcu-
lated the Charlson comorbidity index using the coding
algorithm described by Sundararajan et al. (2004) [21]
on all ICD-10 codes in claims in the 2 years prior to the
diagnosis of lung cancer and included the distinct Charl-
son conditions as binary variables (comorbidity yes /
no). As slight modifications from the initial algorithm,
lung cancer was excluded from the condition ‘cancer’.
Furthermore, we disregarded the condition ‘metastatic
carcinoma’ to avoid a multicollinearity issue with the
variable metastases location at baseline.
Economic implications
To assess the economic implications of inhospital death
we calculated expenditures for the health insurance
company in the last 30 days before death. We compared
total all-cause expenditures for hospitalizations, doctor
visits and medications between patients with inhospital
death to those who died elsewhere.
Statistical methods
To investigate potential differences between lung cancer
patients dying in a hospital and those dying elsewhere,
we compared means, standard derivations (SD) medians
and frequencies of basic variables like, gender, age and
need for care. Categorical variables were compared using
the χ2-test. Only age was approximately normally dis-
tributed (visual inspection) and compared using t-test
(pooled test for equal variances). All other categorical
Fig. 1 Patient flow diagram
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variables were compared with Wilcoxon U-test for non-
normal distributions. We compared survival trends of both
groups via Kaplan-Meier curves and Log-Rank tests.
To examine the relationship between the related
factors described above and inhospital death we used a
multivariate logistic regression model and chose LASSO
(“least absolute shrinkage and selection operator”) as the
selection method [22]. LASSO selection combines some
of the favourable properties of stepwise regression (ease
of interpretation) and ridge regression (robustness) [22]
while additionally performing better concerning multi-
collinearity [23, 24]. The first part of the LASSO loss
function is equal to an ordinary least square regression,
whereas the second part constrains the absolute value of
the sum of the regression estimates by the parameter. It
















where L is the loss function, X is an n × p design matrix
for predictors, Y is an n × 1 vector of responses, β is a
p × 1 vector of regression coefficients, and λ ≥ 0 is the
regularization parameter that controls the degree of
shrinkage. Because the penalty term ðλPpj¼1 jβ jjÞ is
based on the sum of the absolute values of the regres-
sion estimates, some estimates can be shrunken to
exactly zero, which results in their exclusion from the
model. That enables LASSO to be used for selection of
predictor variables [25]. The LASSO loss function is not
differentiable because of the unknown parameter λ.
Thus, we used the method proposed by Nesterov (2013)
to minimize the function while optimizing λ [26]. Age
and sex were considered as pre-fixed covariates. To cal-
culate odds ratios (ORs), 95%-confidence intervals (CIs)
and p-values, we ran a logistic regression model with the
covariates identified by LASSO selection. In this regard,
it should be noted that all variables chosen by LASSO
selection have an important influence on the outcome
variable, irrespective of their statistical significance
within the subsequent logistic regression model.
As expenditures did not show a normal Gaussian dis-
tribution using linear regression (OLS) was not possible.
Therefore, we used a Generalized Linear Model (GLM)
with gamma distribution and log link function. This kind
of model is able to handle data that are right-skewed
and eliminates heteroscedasticity [27]. The derivate of
the parameter estimates from gamma regression repre-
sent the additive effect (in expenditures) that a change
in this variable would cause. To interpret these results
more easily, healthcare expenditures were reported as
recycled predictions with confidence intervals and
p-values. Recycled predictions are used to understand
the marginal effect of independent variables on a
dependent variable. They are obtained from the gamma
regression model by averaging predicted scores, after
fixing the value of one independent variable (either
inhospital death, or death elsewhere), and using ob-
served values on the remaining independent variables.
The recycled predictions then provide adjusted means
for both groups [28]. All recycled prediction models
were adjusted by the factors identified as being associ-
ated with inhospital death earlier. The parameter esti-
mates obtained from this gamma GLM are provided as
Additional file 1.
Confidence intervals and p-values of the adjusted
means and difference were based on non-parametric
bootstrapping (1000 bootstrap repetitions, percentile
method). We used a significance level of 5% for all
analyses.
To examine the robustness of the model we ran three
sensitivity analyses (SA). For SA1 we extended the defin-
ition of inhospital death to include patients who were
discharged from the hospital in the week before death
and spent at least 2 days in the hospital in that week
(additional 825 patients in inhospital death group). We
chose the last week of life because it is defined as phase
of death and we assumed that hospitalization in that
final phase might correlate particularly strong with a de-
creased QoL [29]. Because our definition of inhospital
death did not reflect whether a patient died on a general
ward or on a palliative ward we ran SA2. Here, we
reassigned 572 patients with inhospital death who had
palliative treatments during the hospital stay of death to
the group with death elsewhere. To avoid missing
important information about patients with fulminant
presentation (death during the first 30 days after diagno-
sis) we did not exclude these patients in SA 3 and
performed the analysis with a sample of 13,090 patients.
All statistical analyses were performed using SAS ver-
sion 9.4. Figures and tables were created with Microsoft
Word, Power Point and Excel.
Results
Patient population and univariate analysis of factors
related to inhospital death
Of the final study sample, 6965 individuals (55.9%) died
in a hospital (Table 1). Patients with inhospital death
were significantly younger than patients who died out-
side a hospital. Most of the patients were male (71.7%)
with a significantly higher proportion of males in the
inhospital death group. The residential setting was com-
parable in both groups regarding regional (Eastern vs.
Western Germany) as well as structural (urban vs. rural)
aspects. Nursing home residency was significantly less
common in the inhospital death group, even though
only few patients (7.7%) lived in a nursing home at all.
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Further, need for care was significantly less severe in
those dying in a hospital. Mean Charlson comorbidity
score did not differ significantly between the two groups.
Patients dying in a hospital significantly more often had
thoracic metastases (34.5% vs. 32.8%), other metastases
locations did not differ.
Median survival was lower in patients dying in the
hospital and the log-rank test showed significantly differ-
ent survival between the two groups (Fig. 2).
Patients dying in a hospital were hospitalized signifi-
cantly more often (10.9 vs. 8.4 days per month survived,
p-value < 0.0001) and visited outpatient doctors signifi-
cantly more frequently (3.1 vs. 2.8 visits per month
survived, p-value < 0.0001).
The proportion of patients with inpatient palliative
care was significantly higher in patients with inhospital
death (18.0% vs. 13.4%, p-value < 0.0001) and the pro-
portion of patients with outpatient palliative care was
significantly higher in patients who died elsewhere (7.7%
vs 1.6%, p-value < 0.0001).
The proportion of patients receiving chemotherapy in
the last 30 days of life was significantly higher in the
inhospital death group (30.0% vs. 16.7%, p-value <
0.0001). Overall, almost one-fifth of patients did not
receive any tumour-directed therapy between diagnosis
and death (n = 2.124, 17.1%). The proportion of patients
not receiving cancer-directed therapy was significantly
lower in the inhospital death group (12.9% vs 22.4%,
p-value < 0.0001). Descriptive statistics of healthcare
utilization, palliative care and therapy are displayed
in Table 2.
Regarding comorbidity burden, dementia was signifi-
cantly less prevalent in the inpatient death group,
whereas the prevalence of peripheral vascular disease,
diabetes with complications and renal disease was
significantly higher (Fig. 3).
Multivariate analysis of factors related to inhospital death
The LASSO method selected the following as factors re-
lated to inpatient death: length of survival in months,
nursing home residency, care level, number of hospital
days, inpatient and outpatient palliative care, chemother-
apy in the last 30 days of life, presence of congestive
heart failure (CHF), and renal disease, as well as cerebral
metastases (Table 3). Longer survival since diagnosis
increased the odds of inhospital death. Nursing home
residency, and increasing need for care reflected by
higher care levels decreased the odds. Having spent
Table 1 Description of the study sample
Entire sample Inhospital death No Inhospital death p-valuec
n (%) 12,457 (100) 6965 (55.9) 5492 (44.1)
Mean age at death (SD) 69.9 (10.0) 68.8 (10.0) 71.4 (9.9) < 0.0001
Sex
Male N (%) 8930 (71.7) 5070 (72.8) 3860 (70.3) 0.002
Survival
Median survival in months 7 7 8 < 0.0001
Living in a nursing home a (%) 958 (7.7) 188 (2.7) 770 (14.0) < 0.0001
Care level a
No care level N (%) 4958 (39.8) 3769 (54.1) 1189 (21.7) < 0.0001
1 N (%) 2451 (19.7) 1324 (19.0) 1127 (20.5) 0.0351
2 N (%) 3416 (27.4) 1376 (19.8) 2040 (37.1) < 0.0001
3 N (%) 1632 (13.1) 496 (7.1) 1136 (20.7) < 0.0001
State
Western Germany N (%) 9724 (78.1) 5478 (78.7) 4246 (77.3) 0.0732
Urban district b N (%) 7829 (62.9) 4380 (62.9) 3449 (62.8) 0.922
Mean Charlson Comorbidity Score (SD) 3.77 (2.65) 3.81 (2.66) 3.72 (2.63) 0.0777
Body regions with Metastases
Cerebal N (%) 2271 (18.2) 1237 (17.8) 1034 (18.8) 0.1256
Bones N (%) 2845 (22.8) 1630 (23.4) 1215 (22.1) 0.0912
Thoracic N (%) 4207 (33.8) 2406 (34.5) 1801 (32.8) 0.0402
a Data of the last quarter before death were used
b Urban district is based on the district types defined by the Federal institute for Research on Building, Urban Affairs and Spatial Development for 2014. Urban
district contains district type 1 and 2, the reference category rural district contains district type 3 and 4
cp-values were calculated with t-test for age at death, Wilcoxon U-test for Charlson Comorbidity Score and Chi2 test for sex, living in a nursing home, care level,
state and urban district
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Fig. 2 Kaplan-Meier-Curve to compare the survival of patients depending on place of death
Table 2 Descriptive statistics of healthcare utilization, palliative care and therapy
Entire sample Inhospital death No Inhospital death p-valuec
n (%)
Healthcare utilization a
12,457 (100) 6965 (55.9) 5492 (44.1)
Number of hospital days (SD) 9.8 (8.2) 10.9 (8.7) 8.4 (7.3) < 0.0001
Number of outpatient doctor visits (SD) 3.0 (2.4) 3.1 (2.6) 2.8 (2.2) < 0.0001
Number of outpatient hospital visits (SD) 0.01 (0.1) 0.01 (0.1) 0.02 (0.1) 0.0559
Palliative Care
Inpatient palliative care N (%) 1994 (16.0) 1256 (18.0) 738 (13.4) < 0.0001
Outpatient palliative care N (%) 2388 (4.3) 111 (1.6) 425 (7.7) < 0.0001
Chemotherapy in last 30 days of life (%) 3009 (24.2) 2090 (30.0) 919 (16.7) < 0.0001
Treatment b
No treatment N (%) 2124 (17.1) 896 (12.9) 1228 (22.4) < 0.0001
Chemotherapy N (%) 2990 (24.0) 1745 (25.1) 1245 (22.7) 0.002
Radiotherapy N (%) 967 (7.8) 512 (7.4) 455 (8.3) 0.0532
Surgery N (%) 715 (5.7) 421 (6.0) 294 (5.4) 0.0996
Chemotherapy and Radiotherapy N (%) 3169 (25.4) 1867 (26.8) 1302 (23.7) < 0.0001
Chemotherapy and Surgery N (%) 1016 (8.2) 632 (9.1) 384 (7.0) < 0.0001
Radiotherapy and Surgery N (%) 301 (2.4) 158 (2.3) 143 (2.6) 0.2263
All three types N (%) 1175 (9.4) 734 (10.5) 441 (8.0) < 0.0001
a Healthcare utilization by month survived between diagnosis and death
b Information if patients received this combination of treatments at any time of the observation period. Number or order of treatments was not considered
cp-values from Wilcoxon U-test for healthcare utilization, and from Chi2 test for treatment and palliative care
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more days in a hospital and receiving inpatient palliative
care increased the likelihood for inhospital death
whereas receiving outpatient palliative care resulted in a
lower risk for inhospital death. If a patient received
chemotherapy in the last 30 days of life, he was more
likely to die in a hospital setting. Patients with CHF, or
renal disease had an increased risk of inhospital death.
Furthermore, patients with cerebral metastases had a
decreased risk of inhospital death.
Multivariate analysis of expenditures
All-cause total costs were significantly higher for
patients dying in a hospital (€ 6852 vs. € 3.254, p-value
< 0.0001). Hospitalizations made up the biggest part of
expenditures and were significantly higher in patients
with inhospital death (€ 5895 vs. € 2321, p-value <
0.0001). Expenditures for doctor visits were significantly
higher in patients who did not die in a hospital (€ 358
vs. € 245, p-value < 0.0001), as were expenditures for
medications (€ 691 vs. € 585, p-value < 0.0001).
Sensitivity analyses
The results of SA1 (Additional file 2) and the main ana-
lyses were similar, however the LASSO method did not
result in an inclusion of renal disease as an important
factor anymore. The results of SA2 (Additional file 2)
and the main analyses differed in two aspects. First,
chronic pulmonary disease (CPD) was selected as im-
portant factor additionally, increasing the odds of inhos-
pital death. Second, inpatient palliative care now
decreased the likelihood of inhospital death.
The model in SA3 was almost the same as in the main
analysis, some effect sizes changed in decimal places only.
Discussion
In our study, we sought to identify factors related to
inhospital death in German lung cancer patients. We
found that especially the patients’ age and frailty, as
measured in the need for care and nursing home resi-
dency, were important factors related to not dying in a
hospital. In addition, patients with cerebral metastases
had a decreased risk of inhospital death. The utilization
of outpatient palliative care also reduced the likelihood
of inhospital death but receiving inpatient palliative care
increased the likelihood of inhospital death. Further-
more, a higher number of days spent in a hospital, CHF
and renal disease, as well as receiving chemotherapy in
the last 30 days of life were associated with an increased
risk of inpatient death.
Total healthcare expenditures were about twice the
expenditures of dying elsewhere, with expenditures for
hospitalizations predominantly responsible for these
Fig. 3 Prevalence of Charlson comorbidity groups depending on place of death
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differences. Although expenditures for outpatient care
and medications were higher in patients not dying in the
hospital, the sum of these differences were negligible
compared to the differences in inpatient expenditures.
Evidence, in which direction age affects inhospital
death is inconclusive: Dasch et al. found a negative asso-
ciation for the general population in a North Rhine-
Westphalia-based study (< 60 versus > 80 years: OR 1.41,
p-value 0.001) [30], but O’Dowd et al. observed a posi-
tive association among lung cancer patients in the UK
(> 85 year vs. 70–74 years OR 1.16; 95% CI 1.08–1.24)
[14]. Finally, Escobar Pinzón et al. (2011) found no
association at all between age and place of death in a
population of Rhineland-Palatinate, however this study
was not focused on lung cancer patients but referred to
the general population [4]. We believe that our observa-
tion of negative association is plausible: Younger patients
may be subject to more aggressive inpatient therapy.
Therefore, their primary clinical relationship is rather with
an oncologist than with a palliative care team. Moreover,
they might have more social/familial obligations than
older patients and death at home may not be desirable if
they have a young family at home. Consequently, younger
patients have an increased risk of inpatient death.
Longer survival after diagnosis increased the risk of
inhospital death. This was a surprising result at first as
we assumed that patients with shorter survival have less
time to come to terms with impending death, and
therefore to organize their final days in a preferred and
comfortable place. However, if a patient is diagnosed in
a late stage of the disease the focus of care is more likely
to be on palliation and organizing end-of-life care rather
than curative therapy. In line with that, patients with
cerebral metastases at time of diagnosis died in the
hospital less frequently.
In our study nursing home residency was associated
with a reduced likelihood of dying in a hospital. This
might be explained by the fact that continuous nursing
care — as often required at end of life — is already avail-
able in this setting, whilst it can often not be guaranteed
in an ambulatory setting. Even though dying in a nursing
home or in a hospice is not the same as dying at home,
most patients prefer those places to hospitals [2]. Rela-
tives who are not able to arrange care of the patients at
home due to financial or other reasons, thus should be
supported more relating organization of accommodation
in a hospice or a palliative care facility in order to in-
crease the patient’s QoL during the last days. Wye et
al. (2014) describe that arranging care outside the
hospital is a very tough task for the relatives [31]. For
this reason, the UK has implemented end of life care
services, which provide nurses who support relatives
with organizational services, as well as assistance with
decision-making. These nurses are supposed to offer
time for conversations with the patients and the rela-
tives about death, as well as the practical aspects of
caring for the dying. This concept works especially
for cancer patients who are close to death and should
be considered as a developing concept to further im-
prove end of life care in Germany. Actually, at the
time this study was conducted, there was study on-
going to evaluate establishing a system of ‘social care
nurses’ in cancer therapy in Germany funded by the
German Ministry of health.
Our study indicated that patients with lower care
levels are more likely to die in a hospital. Escobar Pinzón
et al. (2011) found similar results in his study (care level
3 vs no care level: OR (death elsewhere vs inhospital
death) 4.95, p-value < 0.0001) [4]. The higher the care
level the higher the need for support in various aspects
of everyday life. Thus, comprehensively dealing with the
organization of the required care has already taken
place. If a home-care setting for a person with high
nursing needs has been organized previously, it is far
easier to enable the patients dying outside a hospital –
as hospitalization is necessary less frequently, and rela-
tives are able to handle complications outside a hospital
(with assistance of professionals).
Table 3 Results of the logistic regression
OR a, b 95% CI a, c p-value
Age at death 0.985 0.98–0.989 < 0.0001
Sex
Male vs female 0.95 0.87–1.04 0.2533
Survival in months 1.01 1.006–1.02 < 0.0001
Living in a nursing home 0.25 0.21–0.30 < 0.0001
Care level (reference = no care level)
1 0.47 0.42–0.53 < 0.0001
2 0.26 0.24–0.29 < 0.0001
3 0.16 0.14–0.19 < 0.0001
Healthcare utilisation
Number of hospital days d 1.04 1.036–1.05 < 0.0001
Palliative Care
Inpatient palliative care 1.85 1.66–2.08 < 0.0001
Outpatient palliative care 0.25 0.20–0.32 < 0.0001
Chemotherapy in last 30 days of life 1.61 1.46–1.77 < 0.0001
Charlson Comorbidities Groups
Congestive Heart Failure 1.21 1.11–1.33 < 0.0001
Renal Disease 1.19 1.08–1.32 0.0006
Body regions with Metastases
Cerebral metastases 0.86 0.77–0.96 0.0050
a Values are rounded to two decimals except if they would be rounded to
exactly 1 then they are rounded to three decimals
b Odds ratio
c 95% confidence interval
d Healthcare utilization by month survived between diagnosis and death
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According to our study, CHF and renal diseases
increased the probability of inhospital death. These
comorbid conditions tend to require intense treatments
and are associated with a high likelihood of complica-
tions. Managing these complications often requires fur-
ther inpatient hospital care [32]. However, it should be
examined whether it is possible to further train formal
and informal care-givers to manage these conditions
outside the hospital.
If a patient in our study received inpatient palliative
care, he was more likely to die in a hospital setting. This
finding was unsurprising as inpatient palliative care is
administered in a hospital for example on a palliative
care ward. Our SA 2 supports this assumption as in this
analysis we regrouped patients from the inhospital death
group, if they had an inpatient palliative care treatment
in the hospital stay of death. Resulting in the effect of
inpatient palliative care changing direction and now
reducing the likelihood of inpatient death.
Given, that outpatient palliative care was per se pro-
vided on a low level among patients of the inhospital
death group, a conclusive interpretation of these results
is limited to some extent. By trend, our analyses support
the study of Purdy et al. (2015), which reported that
patients receiving outpatient palliative care for a longer
duration were less likely to die in a hospital. Patients
and relatives using palliative care have usually already
confronted the fact of impending death. Most families
feel overburdened in this situation. The providers of
palliative care are in a better position to assist the family
with decision-making and to help them with enabling
the patient’s death in a preferred place – mainly because
there is sufficient time and opportunity for such conver-
sations. Furthermore, palliative care providers have a
broad base of knowledge about the health care system as
well as local supply structures. In addition, engaging
with outpatient palliative care may define a population
who are more determined to die at home. Purdy et al.
(2015) [33] demonstrated that an end of life coordin-
ation centre that aims to help patients under palliative
care be cared for in their preferred place, can reduce the
number of inhospital deaths significantly (OR 0.33,
p-value < 0.001).
In contrast to receiving palliative care, the administra-
tion of chemotherapy in the last 30 days of life was
associated with an increased likelihood of inhospital
death. Receiving chemotherapy shortly before death can
be considered as an aggressive treatment and deemed
undesirable by some clinicians [34, 35], even though it
needs to be kept in mind that palliative care could to
some extent also include chemo-therapeutic measures.
That these patients more often die in a hospital could be
explained by the close relationship between the patient
and the oncologist who is often located in a hospital.
Furthermore, death might be associated with the treat-
ment itself while in the hospital.
Similar reasons could play into the finding that
patients with a higher number of hospital days also have
a higher likelihood of inpatient death. A higher number
of hospitalizations may indicate a more aggressive or
longer tumour-directed treatment. Therefore, patients
have an established relationship with the hospital and its
clinicians and associate them rather than a palliative care
team with the primary point of contact.
Despite higher comorbidity burden, patients in the
inhospital death group were less frail as measured in
care level and nursing home residency. Therefore, we
can deduct that it’s not the patients’ frailty that has an
impact on the place of death as these patients are
already cared for at diagnosis, but more importantly
specific comorbidities. Therefore, these comorbidities
are important aspects to consider when lung cancer is
diagnosed.
As expected, we found that expenditures for inpatient
care were around double in the inhospital death group.
However importantly, we could see that the excess costs
in the outpatient sector for patients who did not die in
the hospital were almost negligible. From this, we can
conclude that not only costs for hospitalizations are
much higher, but also additional expenditures for
outpatient care are extremely low.
Thus, extending outpatient palliative care services as it
currently happens in Germany will probably create a
win-win situation for patients and the SHI system, since
the expected decline in expenditures for inpatient care
would compensate for the additional expenses in the
outpatient sector. Our results are supported by the stud-
ies of Faßbender (2005) [36] and Smith et al. (2012) [37]
who found that palliative care might have a cost-cutting
effect because of fewer therapeutic interventions not
primarily aiming at improving QoL for terminally ill
patients. Thereby the need for inpatient treatments
might be reduced and patients remain in a stable condi-
tion while still receiving sufficient medical and
non-medical care.
Most limitations in our study stem from the use of
claims data, which are primarily documented by health-
care providers for billing purposes with health insurance
funds. The exact place of death is not important for
these parties and is therefore not documented. This is
the reason that within this study we have only been able
to distinguish between inhospital death and death
elsewhere. We do not know if patients in the inhospital
death group died on a palliative ward or on a normal
ward, nor can we differentiate between various places of
death outside a hospital such as a hospice or the family
home. Owing to data protection laws, data contained
only year and month of death for those who died in an
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outpatient setting. We used rules to define a more valid
date of death but there are still possible differences to
the actual date of death of up to 2 weeks for each indi-
vidual. As O’Malley et al. (2005) described, the coding of
ICD- and OPS-codes is a source of error in itself [38]
which can e.g. arise out of unintentional and intentional
coder errors, such as misspecification, unbundling, and
up-coding. This should be considered when interpreting
variables based on those codes like Charlson comorbid-
ity groups. For historical reasons, the average income
and the family structure of AOK-insured people may
differ from the general German population. When there
was no free choice of health insurance provider, the
AOK as a Local Health Care Funds insured the general
population (workers, retirees, family members) in
contrast to company-provided health insurance funds,
which for example insured predominantly persons with
higher incomes and who tends to be healthier. Even now
when all members of the population are in the position
to choose their own health insurance provider, this
structure is still visible. However, Jaunzeme et al. (2013)
have shown that these differences are small enough to
assume that the population of AOK-insured and
herewith our results are representative for the German
resident population [39].
Our study represents the first nationwide examination
of factors possibly related to inhospital death in German
lung cancer patients such as the patients’ care needs,
comorbidity burden, lung cancer-related treatments, and
regional aspects. More importantly, we could provide
expenditures for inhospital death not only as total but
also for different aspects of care and therefore provide
evidence that investments in palliative care can never-
theless reduce expenditures in total. As an innovative
methodological approach, we applied the LASSO selec-
tion method which combines the easy interpretability
and robustness. LASSO selection has been shown to
outperform other selection methods like stepwise selec-
tion [40]. Finally, our analyses are automatically based
on a multicentre study, whereby biases resulting from
specific documentation rules and approaches of single
healthcare providers are avoided. Thus, we are con-
vinced that these analyses create a sound starting point
for conditions that need to be considered when trying to
create an environment supporting terminally ill-patients
to make a more self-determined decision on where to
spend their last days of life.
Conclusion
This study provides further evidence about factors re-
lated to inhospital death in German lung cancer patients.
Findings suggest that factors associated with inhospital
death often relate to previous contacts with hospitals.
This includes prior hospitalizations, tumour-directed
treatment and treatment of comorbidities. Additionally,
factors associated with dying elsewhere relate to access
to other care settings than hospitals where therapy is
focused more on palliation. From these results we can
implicate that an early or earlier integration of palliative
care into tumour-directed therapy might be a useful tool
in helping patients to make informed decisions in the
last phase of their life, by using established relationships
e.g. with the oncologist. Additionally, further expanding
the palliative supply network, can be achieved while still
reducing costs for SHIs.
Endnotes
1Care level I: People who need assistance with
personal hygiene, feeding or mobility for at least two
activities from one or more areas at least once a day,
and who additionally need help in the household several
times a week for at least 90 min a day with 45 min
attributable to basic care.Care level II: People who need
assistance in at least two basic activities of daily living
(ADLs) at least three times a day at various times and
additional help in I ADLs several times a week for at
least 3 h a day, with 2 h attributable to basic care.Care
level III: People who need assistance in at least two
ADLs around the clock and additional help in an IADL
several times a week for at least 5 h per day, with 4 h
attributable to basic care.
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